Reported 23 days ago
In his recent discussion on CNBC, Jim Cramer provided insights into the pharmaceutical giant Bristol-Myers Squibb Co (NYSE:BMY), emphasizing the company's strategic missteps, particularly regarding ill-advised business spinoffs. While he praised its potential in handling schizophrenia with its COBENFY drug, he pointed out that the company’s low PE ratio reflects deeper issues in its pipeline. Additionally, Cramer highlighted the broader challenges facing tech stocks amidst market uncertainties, noting the significant impact of tariffs and taxes on their valuations.
Source: YAHOO